

Psoriasis Drugs: Market Research Report



Phone: +44 20 8123 2220
Fax: +44 207 900 3970
office@marketpublishers.com
<http://marketpublishers.com>

Psoriasis Drugs: Market Research Report

Date:	April 1, 2010
Pages:	568
Price:	US\$ 3,950.00
ID:	PA18DA15860EN

This report analyzes the worldwide markets for Psoriasis Drugs in US\$ Million by the following Drug Administration Routes - Systemic Drugs, and Topical Drugs.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Ammirall SA, Astellas Pharma US, Inc., Biogen Idec, Inc., Eisai Co.Ltd., Galderma Laboratories, Isis Pharmaceuticals, Inc., Johnson & Johnson Company, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Stiefel Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Vertex Pharmaceuticals, Inc., and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Table of Content

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Systemic Drugs
- Topical Drugs

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Psoriasis – A Chronic, Widespread Autoimmune Disease

Table 1. World Psoriasis Prevalence (in Million) in Select Countries: 2007-2015 (includes corresponding Graph/Chart)

- Psoriasis Poses Risk for Cardiovascular Diseases
- Quick Facts About Psoriasis Disease
- Quick Facts About Psoriasis Treatment
- Global Market Outlook
- Psoriasis Drugs Overview

Major Marketed Drugs for Psoriasis Treatment as of 2009 Topical Drugs Overview

Table 2. World Psoriasis Drugs Market – Value Sales of Select Leading Topical Products in US\$ Million for 2008 (includes corresponding Graph/Chart)

Foams and Liquid Formulations Gaining Momentum
JAK3 Inhibitors Spell Promising Future for Topical Drugs
Systemic Drugs Overview

Table 3. World Psoriasis Drugs Market – Value Sales of Select Leading Conventional Systemic Products in US\$ Million for 2007 (includes corresponding Graph/Chart)

Enbrel – The Market Leader

2.KEY MARKET TRENDS

Market Welcomes New Products, Even As Established Biologic Makes Exit
Conventional Topical Therapies to Remain Mainstay Treatment
Biologics to Witness Robust Growth, Driven by New Product Introductions
Interleukin and TNF-Alpha Inhibitors to Drive Biologics Growth
TNF-Alpha Blockers – The Market Leaders

Table 4. World Psoriasis Drugs Market – Value Sales of Select Leading Biologic Systemic Products in US\$ Million for 2008(includes corresponding Graph/Chart)

Interleukin Inhibitors – The Next Big Biologic Class
Non-Prescriptions and Generics Threaten Market Growth
Oral Pipeline Therapies To Take On Biologics
Home Ultraviolet B Therapy to Find Favor with Psoriasis Patients
Paradigm of Psoriasis Treatment
Voclosporin to Edge Out Competitive Products
Apremilast to OUTdo Existing Anti-TNF Products

3.PIPELINE ANALYSIS

The Research Progress in Psoriasis Treatment
Safety Plays Critical Role in Psoriasis Therapy
Major Drug Candidates in Pipeline
Existing and Future Research & Development Approach

Table 5. Psoriasis Drugs Pipeline (2009) - Number of Pipeline Candidates and Clinical Trials (includes corresponding Graph/Chart)

Select Psoriasis Pipeline Candidates for Topical Treatment as of 2009
Select Psoriasis Pipeline Candidates for Oral Treatment as of 2009
Select Psoriasis Pipeline Candidates for Injectable Treatment as of 2009
Other Major Psoriasis Pipeline Candidates in Phase II Clinical Trials as of 2009
NIAID Researchers Identify Potential New Drug Target

4.ALL ABOUT PSORIASIS

What is Psoriasis?

The History of Psoriasis

The History of Psoriasis Treatment

The Risk Factors of Psoriasis

The Cause(s) of Psoriasis

The Aggravating Factors

The Diagnosis of Psoriasis

The Severity of Psoriasis

The Types of Psoriasis

Plaque Psoriasis

Scalp Psoriasis

Nail Psoriasis

Inverse Psoriasis

Guttate Psoriasis

Pustular Psoriasis

Erythrodermic Psoriasis

Psoriatic Arthritis

Others

The Treatment of Psoriasis

The Three-Step Approach to Treatment

Treatment by Disease Severity

Mild Stage Psoriasis Treatment

Moderate Stage Psoriasis Treatment

Severe Stage Psoriasis Treatment

Treatment by Natural Healing

Other Treatment

5.OVERVIEW OF PSORIASIS TREATMENT

Table 6. Therapeutic Modalities for Psoriasis Treatment in Percentage by Disease Stage (includes corresponding Graph/Chart)

Topical Treatment

List of Topical Therapies Available for the Treatment of Mild-to-Moderate Psoriasis

Select Topical Drugs

Clobex (Clobetasol propionate)

Dovonex (calcipotriene)

Olux-E (Clobetasol propionate)

Taclonex/ Dovobet/ Daivobet (calcipotriene/ betamethasone)

Tazorac (Tazarotene)

Vectical (calcitriol)

Systemic Treatment

Select Conventional Systemic Drugs

Methotrexate

Soriatane (acitretin)

Neoral (cyclosporine)

Tegison (etretinate)

NSAIDs

Biologic Systemic Therapies

List of Approved Biologic Systemic Therapies for Psoriasis

Select Biologic Drugs

Amevive (alefacept)

Enbrel (etanercept)

Humira (adalimumab)
Remicade (infliximab)
Raptiva (efalizumab)
Stelara (ustekinumab)
Phototherapy
UVB Phototherapy
PUVA Phototherapy
Alternative Treatment
Climatotherapy

6.SELECT CLINICAL TRIALS

Isotechnika's Voclosporin Shows Favorable Results in Phase III Clinical Trial
Provectus Commences New PH-10 Clinical Trials for Psoriasis
Micromet Initiates First Clinical Study for GM-CSF Human Antibody MT203
Welichem Initiates GLP Toxicology Studies for WBI-1001
Anacor Announces Favorable Phase II Trial Results of AN2728
Synvista Initiates Phase II Clinical Trial of Topical SYI-2074
Avontec Announces Positive Results from Phase IIa Clinical Trial of AVT-02 UE
Revotar Announces Favorable Phase I Trial Results of Bimosiamose 5% Cream
Manhattan Completes Enrollment in Phase IIa Clinical Trial of Topical PTH (1-34)
Dermipor Announces Positive Results from Phase IIb Clinical Trial of DPS-101
BioCryst Completes Phase IIa Study, Announces Promising Results of BCX-4208
Arana Therapeutics Completes Patient Recruitment in Phase II Trial of ART621
Novartis Exploratory Development Study Shows Positive Results for AEB071

7.PRODUCT LAUNCHES/ APPROVALS

Eisai Obtains Japanese Approval for HUMIRA® in Psoriasis Treatment
Janssen-Cilag Launches Stelara® for Plaque Psoriasis
PsoriasisDX Launches Genetic Test for Psoriatic Arthritis
Elorac Launches Zithranol-RR for Plaque Psoriasis
Quinnova Introduces New Treatment for Hyperkeratotic Conditions
Xderma Launches New Ointment for Psoriasis
Promius Pharma Introduces Scytera Foam 2% for Chronic Psoriasis
NeoStrata Launches PSORENT
LEO Pharma to Launch Xamiol®
Glenmark Introduces Dermatology Products
The Kuwait Health Ministry Approves Alalorid for Psoriasis Treatment
CHMP's Positive Recommendation for Enbrel as Psoriasis Treatment in Children

8.RECENT INDUSTRY ACTIVITY

Cephalon Acquires Arana Therapeutics
GlaxoSmithKline to Acquire Stiefel Laboratories
PhotoMedex Acquires Photo Therapeutics
PPD Acquires Magen BioSciences
Bristol-Myers Squibb Acquires Medarex
Valeant Pharmaceuticals Acquires Dow Pharmaceutical Sciences
Advitech to Acquire Botaneco Specialty Ingredients
Merck Merges with Schering-Plough
Pfizer Acquires Wyeth
Paladin Labs and Isotechnika Pharma Enter into Partnership
Centocor Ortho Biotech Obtains FDA Approval for Golimumab
Centocor Ortho Biotech Obtains FDA Approval for Stelara™

Galderma Receives Approval from FDA for Vectical
LEO Pharma Reacquires Product Licensing Rights from Warner Chilcott
Genentech Withdraws Raptiva from US Market
Prime Pharmaceutical Grants License of Relieva® to Mac Pharma
Dynavax Receives Grant to Support TLR Inhibitors Development from NIAID
Valeant Pharmaceuticals Takes Over DermaTech
Bayer Takes Over Direvo Biotech
Stiefel Laboratories Acquires Barrier Therapeutics
Biotie Therapies Enters in Agreement to Acquire elbion
Galderma Acquires Collagenex
Abbott Obtains FDA Approval for HUMIRA® in Psoriasis Treatment
LEO Pharma and Warner Chilcott Obtain FDA Approval for Taclonex Scalp®
Cytos Joins Hands with Pfizer to Develop Vaccines
Karo Bio and Zylus Cadila Enter into Collaboration
DermipSor Collaborates with Department of Veterans Affairs and VA Boston Research Institute
GlaxoSmithKline Signs Deal with Dynavax Technologies
RXi Pharmaceuticals Receives Technology License from UMMS
Heilongjiang Tianlong Receives Manufacturing Rights for Four Medicines
Dara BioSciences Raises Funds for Testing of Drugs
Avidas Pharmaceuticals Acquires Rights from Crown Laboratories
LEO Pharma Sets Up LEO Pharma China
Dr Reddy's Established New Subsidiary in the US
Lupin to Outlicense Psoriasis Drugs

9.FOCUS ON SELECT PLAYERS

Abbott Laboratories (US)
Amgen Inc. (US)
Almirall SA (Spain)
Astellas Pharma US, Inc. (US)
Biogen Idec, Inc. (US)
Eisai Co. Ltd. (Japan)
Galderma Laboratories (Switzerland)
Isis Pharmaceuticals, Inc. (US)
Johnson & Johnson Company (US)
LEO Pharma A/S (Denmark)
Merck & Co., Inc. (US)
Novartis AG (Switzerland)
Stiefel Laboratories, Inc. (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Valeant Pharmaceuticals International (US)
Vertex Pharmaceuticals, Inc. (US)
Wyeth (US)

10.GLOBAL MARKET PERSPECTIVE

Analytics by Geographic Region

Table 7. World Recent Past, Current & Future Analysis for Psoriasis Drugs by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 8. World 10-Year Perspective for Psoriasis Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 and 2015 (includes

corresponding Graph/Chart)

Analytics by Drug Administration Route

Table 9. World Recent Past, Current & Future Analysis for Psoriasis Drugs by Drug Administration Route – Systemic Drugs and Topical Drugs Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 10. World 10-Year Perspective for Psoriasis Drugs by Drug Administration Route – Percentage Breakdown of Dollar Sales for Systemic Drugs and Topical Drugs Markets for Years 2006, 2009 and 2015

III. MARKET

1. UNITED STATES

A. MARKET ANALYSIS

Current and Future Analysis

Major Trends

Corticosteroids: Foundation of Mild to Moderate Treatment

Dovonex, Taclonex Remain Standard Topical Treatments

Room for Biologics Penetration As Most Moderate-to- Severe Cases Remain Untreated for Psoriasis

Enbrel to Lead, Despite Losing Share to Humira

Humira Cuts into Enbrel's Share

Amgen to Redeem 100% North American Rights for Enbrel

J&J's Stelara Unlikely to Take the Market By Storm

FDA Delays Enbrel's Pediatric Psoriasis Indication

Genentech Withdraws Raptiva, Triggers Safety Concerns

Product Launches

Strategic Corporate Developments

Key Players

B. MARKET ANALYTICS

Table 11. US Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2. JAPAN

A. MARKET ANALYSIS

Current and Future Analysis

Key Player

B. MARKET ANALYTICS

Table 12. Japanese Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3. EUROPE

A. MARKET ANALYSIS

Current and Future Analysis
Product Launches
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 13. European Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis
Product Launches
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 14. Rest of World Recent Past, Current & Future Analysis for Psoriasis Drugs Market – Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 75)

Region/CountryPlayers

The United States46

Canada

Japan

Europe

Germany

The United Kingdom

Italy

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

I would like to order:

Product name: Psoriasis Drugs: Market Research Report
Product link: <http://marketpublishers.com/r/PA18DA15860EN.html>
Product ID: PA18DA15860EN
Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <http://marketpublishers.com/r/PA18DA15860EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at http://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**